Advertisement

Supportive Care in Cancer

, Volume 22, Issue 6, pp 1601–1610 | Cite as

Awareness, concern, and communication between physicians and patients on bone health in cancer

  • Debu TripathyEmail author
  • Brian G. M. Durie
  • Beatrice Mautner
  • Krag S. Ferenz
  • Judd W. Moul
Original Article

Abstract

Purpose

This study aims to explore physician–patient communications about bone metastases and cancer treatment-induced bone loss (CTIBL).

Methods

The study utilizes online survey of patients with breast cancer, prostate cancer, and multiple myeloma, and the physicians who treat them.

Results

Even though 69 and 48 % of patients with nonmetastatic breast and prostate cancer aware of treatment-induced bone loss, only 39 and 23 %, respectively, were concerned about bone loss. Yet, 62 and 71 % of oncologists treating breast and prostate cancer felt that their patients were concerned. Among patients with metastatic breast and prostate cancer, two thirds had not discussed treatment for bone metastases with their doctor; when discussed, 88 and 91 % of discussions were initiated by the doctor, usually prior to initiating treatment. Most myeloma patients (77 %) had discussed treatment options with their physicians; 99 % of hematologists reported discussing treatment of bone disease with patients.

Conclusions

Physicians are primary sources of information to patients regarding bone health. There is a gap between what physicians assume their patients know about bone health and the patients’ perceptions, presenting a need for systematic awareness and education.

Keywords

Cancer treatment-induced bone loss Bone metastases Skeletal-related event Prostate cancer Breast cancer Multiple myeloma 

Notes

Acknowledgments

The survey was sponsored by Amgen. The authors thank Supriya Srinivasan, PhD, of Scientia Medical Communications, LLC, for assistance with writing and editing this manuscript.

Conflict of interest

BM was an employee of Amgen at the time the study was conducted and owns Amgen stock. JWM is on Amgen’s speaker bureau for the use of denosumab in prostate cancer. DT, BGMD, and KSF have no conflicts of interest to disclose.

References

  1. 1.
    Body J-J (2010) Prevention and treatment of side-effects of systemic treatment: bone loss. Ann Oncol 21:vii180–vii185PubMedCrossRefGoogle Scholar
  2. 2.
    Vanderwalde A, Hurria A (2011) Aging and osteoporosis in breast and prostate cancer. CA Cancer J Clin 61:139–156PubMedCrossRefGoogle Scholar
  3. 3.
    Pfeilschifter J, DielI J (2000) Osteoporosis due to cancer treatment: pathogenesis and management. J Clin Oncol 18:1570–1593PubMedGoogle Scholar
  4. 4.
    Coleman RE (2006) Clinical features of metastatic bone disease and risk of skeletal morbidity. Clin Cancer Res 12:6243s–6249sPubMedCrossRefGoogle Scholar
  5. 5.
    Lipton A, Theriault RL, Hortobagyi GN et al (2000) Pamidronate prevents skeletal complications and is effective palliative treatment in women with breast carcinoma and osteolytic bone metastases: long term follow-up of two randomized, placebo-controlled trials. Cancer 88:1082–1090PubMedCrossRefGoogle Scholar
  6. 6.
    Saad F, Gleason DM, Murray R et al (2004) Long-term efficacy of zoledronic acid for the prevention of skeletal complications in patients with metastatic hormone-refractory prostate cancer. J Natl Cancer Inst 96:879–882PubMedCrossRefGoogle Scholar
  7. 7.
    Shahinian VB, Kuo YF, Freeman JL, Goodwin JS (2005) Risk of fracture after androgen deprivation for prostate cancer. N Engl J Med 352:154–164Google Scholar
  8. 8.
    Oster G, Lamerato L, Glass AG et al (2013) Natural history of skeletal-related events in patients with breast, lung, or prostate cancer and metastases to bone: a 15-year study in two large US health systems. Support Care Cancer 21(12):3279–3286, 2013 DecPubMedCrossRefGoogle Scholar
  9. 9.
    Siegel R, Naishadham D, Jemal A (2013) Cancer statistics, 2013. CA Cancer J Clin 63:11–30Google Scholar
  10. 10.
    National Comprehensive Cancer Network (2012) Clinical practice guidelines in oncology: multiple myeloma, version 1. 2012. www.nccn.org. Accessed 25 March 2012
  11. 11.
    Berenson JR, Lichtenstein A, Porter L et al (1998) Long-term pamidronate treatment of advanced multiple myeloma patients reduces skeletal events. Myeloma Aredia Study Group. J Clin Oncol 16:593–602PubMedGoogle Scholar
  12. 12.
    National Comprehensive Cancer Network (2012) Clinical Practice guidelines in oncology: breast cancer, version 1. 2012. www.nccn.org. Accessed 25 March 2012
  13. 13.
    National Comprehensive Cancer Network (2012) Clinical practice guidelines in oncology: prostate cancer, version 1. 2012. www.nccn.org. Accessed 25 March 2012
  14. 14.
    Hillner BE, Ingle JN, Chlebowski RT et al (2003) American Society of Clinical Oncology 2003 update on the role of bisphosphonates and bone health issues in women with breast cancer. J Clin Oncol 21:4042–4057PubMedCrossRefGoogle Scholar
  15. 15.
    Cummings SR, Bates D, Black DM (2002) Clinical use of bone densitometry: scientific review. JAMA 288:1889–1897PubMedCrossRefGoogle Scholar
  16. 16.
    Gralow JR, Biermann JS, Farooki A et al (2009) NCCN task force report: bone health in cancer care. J Natl Compr Cancer Netw 7:S1–S32Google Scholar
  17. 17.
    Muusses LD, Weert JCM, Dulmen S, Jansen J (2012) Chemotherapy and information-seeking behaviour: characteristics of patients using mass-media information sources. Psychooncology 21:993–1002PubMedCrossRefGoogle Scholar
  18. 18.
    Rutten LJL, Arora NK, Bakos AD, Aziz N, Rowland J (2005) Information needs and sources of information among cancer patients: a systematic review of research (1980–2003). Patient Educ Couns 57:250–261PubMedCrossRefGoogle Scholar
  19. 19.
    McKean H, Looker S, Hartmann LC et al (2008) Are cancer survivors/patients knowledgeable about osteoporosis? Results from a survey of 285 chemotherapy-treated cancer patients and their companions. J Nutr Educ Behav 40:144–148PubMedCrossRefGoogle Scholar
  20. 20.
    Nagler RH, Gray SW, Romantan A et al (2010) Differences in information seeking among breast, prostate, and colorectal cancer patients: results from a population-based survey. Patient Educ Couns 81:S54–S62PubMedCrossRefGoogle Scholar
  21. 21.
    Lewis N, Gray SW, Freres DR, Hornik RC (2009) Examining cross-source engagement with cancer-related information and its impact on doctor-patient relations. Health Commun 24:723–734PubMedCentralPubMedCrossRefGoogle Scholar
  22. 22.
    Davies NJ, Kinman G, Thomas RJ, Bailey T (2008) Information satisfaction in breast and prostate cancer patients: implications for quality of life. Psychooncology 17:1048–1052PubMedCrossRefGoogle Scholar
  23. 23.
    Martinez LS, Schwartz JS, Freres D, Fraze T, Hornik RC (2009) Patient–clinician information engagement increases treatment decision satisfaction among cancer patients through feeling of being informed. Patient Educ Couns 77(3):384–390PubMedCentralPubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2014

Authors and Affiliations

  • Debu Tripathy
    • 1
    Email author
  • Brian G. M. Durie
    • 2
  • Beatrice Mautner
    • 3
  • Krag S. Ferenz
    • 4
  • Judd W. Moul
    • 5
  1. 1.USC/Norris Comprehensive Cancer CenterUniversity of Southern CaliforniaLos AngelesUSA
  2. 2.Cedars-Sinai Outpatient Cancer CenterLos AngelesUSA
  3. 3.Vantage OncologyManhattan BeachUSA
  4. 4.MSLGROUP AmericasNew YorkUSA
  5. 5.Division of Urology and Duke Cancer InstituteDuke University Medical CenterDurhamUSA

Personalised recommendations